Press Release – NEWARK, Calif. – December 10, 2024 – InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics for cardiac arrythmias, has announced that Myles Greenberg, MD, MBA will serve as its new president and CEO. Dr. Greenberg joins the company as it advances clinical development of its lead product, an orally inhaled treatment for the rapid conversion of recent-onset and symptomatic atrial fibrillation (AF) to sinus rhythm.

InCarda’s lead product is a novel formulation of flecainide administered by oral inhalation.  Flecainide is an antiarrhythmic medicine approved in the United States over 30 years ago as an oral drug for chronic administration, and it is widely used to reduce the risk of recurrent and symptomatic paroxysmal atrial fibrillation (PAF) in patients without structural heart disease.  By administering flecainide via inhalation, InCarda hopes to safely and rapidly restore sinus rhythm thereby bringing faster symptom relief, avoidance or shortening of hospital stay, reduced risk of stroke and heart failure, and better long-term prognosis to patients with recent-onset episodes of PAF.

AF is a dangerous and increasingly common condition affecting approximately 10 million people in the U.S. alone. The condition can cause disabling symptoms that reduce quality of life, and left untreated, can lead to stroke, heart failure, hospitalization and even death. AF is also progressive: more than half of patients with PAF go on to experience persistent atrial fibrillation. The total economic burden to the U.S. healthcare system is estimated at up to $26 billion.

“InCarda’s mission is to enable the growing number of PAF sufferers to take more control of their health by developing a product designed to allow patients eventually to treat their abnormal heart rhythm and symptoms at home,” Dr. Greenberg said. “If we are successful, we can improve patients’ quality of life and help them avoid unnecessary hospitalizations and other complications of their AF.”

Dr. Greenberg comes to InCarda with nearly 25 years of experience in growing life-sciences businesses and developing new products, having served as a CEO, venture investor, and lead board member of many venture-backed companies developing novel medical devices, biopharmaceuticals and healthcare technologies. Dr. Greenberg began his career as a practicing emergency physician and emergency department administrator at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston. He succeeds interim CEO and cofounder Carlos Schuler, PhD, who will transition to chief technology officer.

“Myles has an innate understanding of the challenges in properly treating cardiac arrythmias like paroxysmal atrial fibrillation, where underdiagnosis and undermanagement lead to disease progression, poor outcomes and significant strain on the healthcare system,” said Dan Welch, executive chairman of InCarda Therapeutics. “We are confident that he is the right leader to build InCarda into a key driver of positive change that can address these challenges and improve the standard of care for physicians and patients.”

About InCarda Therapeutics

InCarda Therapeutics is a clinical stage biopharmaceutical company developing novel therapies for cardiac arrhythmias. The company is backed by leading institutional healthcare investors Deerfield Management and HealthCap. Incarda’s lead development program is a novel, orally inhaled formulation of flecainide intended for rapid treatment of recent-onset, symptomatic paroxysmal atrial fibrillation. For more information, visit incardatherapeutics.com.

Media Contact:
Joe Duraes
Pazanga Health Communications
[email protected]
(917) 687-6419

Source : Incardatherapeutics